Stocks-HALO-Halozyme Therapeutics Inc

HALO Halozyme Therapeutics Inc

58.15 0.41 (0.71%)
in USD Market Open
Invest
Invest

Overview

Prev Close57.74
Day's Range 57.07 - 58.43
52 Week Range 31.29 - 59.35
Average Volume (3m)1.23M
1-Year Return75.20%
Beta0.8267
Market Cap7.81B
P/E Ratio38.75
Revenue580.62M
EPS1.49
Dividend (Yield)0 (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Chart times in UTC
Industry Biotechnology
CEO Helen I. Torley, MD
Employees 145

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2021: Halozyme Therapeutics Inc's revenues increased by 65.67% and amounted to 443.31M. Net income increased by 211.97% to 402.71M. Net assets increased by 30.39% to 196.95M and EPS increased from 0.91 to 2.74.
HALO's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
72.90%
Net Profit Margin
13.84%
Operating Margin
46.18%
Return On Investment
20.35%
12/21
03/22
06/22
09/22
Total Revenue
102M
117.28M
152.37M
208.98M
Gross Profit
80.42M
101.36M
118.42M
161.66M
Operating Income
56.53M
75.67M
52.66M
83.29M
Net Income
66.77M
60.11M
22.69M
61.63M